Physician profile
Douglas Kohl
NPI 1912929381
$3,281.08
in general payments reported to CMS, 2019-2025
25 companies · $666 in 2025
The $666 reported for 2025 was more than what 83% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $214 · 2020: $44.26 · 2021: $202 · 2022: $349 · 2023: $835 · 2024: $971 · 2025: $666.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,472.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,471.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,193.59 | 2022-2025 | |
| Alcon Vision LLC | $469.12 | 2022-2025 | Clareon, Rocklatan, Tryptyr |
| Allergan, INC. | $243.80 | 2019-2022 | |
| Rxsight INC | $172.75 | 2022-2025 | Rxsight Injector Handpiece, Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd) |
| Ocular Therapeutix, INC. | $137.55 | 2021-2025 | Dextenza |
| Sun Pharmaceutical Industries INC. | $134.44 | 2023-2025 | Cequa |
| Amgen INC. | $109.61 | 2024-2025 | Tepezza |
| Coopervision INC. | $101.37 | 2023 | Misight Contact Lens |
| Aerie Pharmaceuticals, INC. | $97.09 | 2019-2021 | |
| Sight Sciences, INC. | $95.12 | 2022-2025 | Omni Surgical System, Sion Surgical Instrument |
| Novartis Pharmaceuticals Corporation | $87.54 | 2019-2023 | |
| Mallinckrodt Hospital Products INC. | $85.04 | 2022-2023 | Acthar |
| Ucb, INC. | $50.08 | 2023-2024 | Zilbrysq |
| Harrow Eye, LLC | $47.90 | 2024-2025 | Triesence, Iheezo |
| Oyster Point Pharma, INC. | $38.50 | 2022-2024 | Tyrvaya |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $30.57 | 2023-2024 | Istent Trabecular Micro-Bypass System Model Is3 |
| Astellas Pharma US INC | $27.69 | 2025 | Izervay |
| Akorn, INC. | $25.19 | 2019 | |
| Horizon Therapeutics Plc | $24.26 | 2023 | Tepezza |
| Johnson & Johnson Surgical Vision, INC. | $23.28 | 2019 | |
| Kala Pharmaceuticals, INC. | $21.26 | 2021 | |
| Carl Zeiss Meditec USA, INC. | $20.25 | 2025 | |
| Bausch & Lomb Americas INC. | $19.49 | 2025 | Miebo |
| Halozyme INC | $17.10 | 2019 | |
| Biotissue Holdings INC. | $8.49 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Kohl listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.